Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 13:15 save search
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
Published: 2021-11-12 (Crawled : 13:15) - biospace.com/
IPIX | $0.0042 1.4K
|
Manufacturing
|
| O: 5.38%
H: 15.96%
C: -5.85%
covid phase 2 potential results trials trial trial results covid-19
AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
ongoing phase 1 trial
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
ALDX | $4.015 2.16% 240K
|
Health Technology
|
| O: 1.11%
H: 3.41%
C: 1.76%
new drug dry eye disease eye application eye disease drug phase 3 trial submission enroll
Diamond Therapeutics Announces First Patient Dosed in Clinical Trial Evaluating Low-Dose Psilocybin
Published: 2021-11-08 (Crawled : 13:15) - prnewswire.com
ARMV | $0.005 350
|
| Email alert
Add to watchlist
trial psilocybin
Gates Industrial Reports Third-Quarter 2021 Results
Published: 2021-11-08 (Crawled : 13:15) - prnewswire.com
GTES | $17.63 2.5% 610K
|
Producer Manufacturing
|
| O: -2.54%
H: 1.68%
C: -0.87%
results trial
Gas Insulated Substation Market to Ascend at 5.7% CAGR by 2031 as Demand Grows in Energy-Intensive Industrial Processes: Future Market Insights
Published: 2021-11-08 (Crawled : 13:15) - prnewswire.com
ABLZF | News | $50.158 1.9K
|
Producer Manufacturing
|
| O: 0.09%
H: 0.59%
C: -1.13%
GE | News | $160.66 6.97% 11M
|
Electronic Technology
|
| O: 2.45%
H: 0.0%
C: 0.0%
ABB | News | $37.13 -0.03% 6.4M
|
Producer Manufacturing
|
| O: 0.54%
H: 0.0%
C: 0.0%
POWL | $143.085 5.11% 160K
|
Producer Manufacturing
|
| O: 5.16%
H: 1.42%
C: 1.1%
ema energy trial at-527
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
Published: 2021-11-08 (Crawled : 13:15) - prnewswire.com
ACXP | $1.98 17K
|
Professional, Scientific, and T...
|
| O: 5.06%
H: 1.6%
C: 0.53%
phase 2 trial conference phase 2b
EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
Published: 2021-11-05 (Crawled : 13:15) - biospace.com/
EYPT | News | $18.025 6.34% 370K
|
Health Technology
|
| O: 0.82%
H: 3.75%
C: 3.75%
ongoing eye phase 1 trial conference
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Published: 2021-11-05 (Crawled : 13:15) - biospace.com/
LGVN 4 d | $1.81 -3.21% 200K
|
|
| O: -3.05%
H: 0.61%
C: -5.57%
disease alzheimer phase 2 research trial alzheimer’s alzheimer's disease alzheimer's
Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 1.15%
H: 1.13%
C: -3.77%
drug trial
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.91%
H: 0.06%
C: -1.04%
KYMR | $36.57 6.46% 190K
|
Health Technology
|
| O: -0.5%
H: 3.25%
C: 0.66%
phase 1 positive trial
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
MNPR | $0.63 -0.32% 56K
|
Health Technology
|
| O: 4.88%
H: 7.64%
C: 3.31%
treatment phase 1 phase 1b trial phase 2b soft tissue
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
Published: 2021-10-22 (Crawled : 13:15) - hancockjaffe.com
NVNO | $5.13 4.48% 40K
|
Manufacturing
| Email alert
Add to watchlist
trial
Gates Industrial Announces Third-Quarter 2021 Earnings Release Date
Published: 2021-10-20 (Crawled : 13:15) - prnewswire.com
MS | News 0 d | $93.71 1.76% 2.2M
|
Finance
|
| O: -0.66%
H: 0.83%
C: -0.42%
GTES | $17.63 2.5% 610K
|
Producer Manufacturing
|
| O: 0.24%
H: 1.08%
C: 0.6%
trial
Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress
Published: 2021-10-20 (Crawled : 13:15) - globenewswire.com
EDIT | News | $5.66 1.07% 750K
|
Health Technology
|
| O: 0.64%
H: 0.71%
C: -2.76%
europe ongoing phase 1 therapy trial
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $5.485 11.03% 24M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 140K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
Ballard to Power Talgo Fuel Cell Passenger Train in European Trial, Ahead of Planned 2023 Launch
Published: 2021-10-12 (Crawled : 13:15) - prnewswire.com
BLDP | $2.59 -1.52% -1.54% 3.4M
|
Producer Manufacturing
|
| O: 1.09%
H: 7.84%
C: 7.4%
europe trial fuel cell train
Industrial Enzymes Market Size to Reach USD 8400.4 Million by 2027 at a CAGR of 4.9% | Valuates Reports
Published: 2021-10-07 (Crawled : 13:15) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
trial
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
Published: 2021-10-07 (Crawled : 13:15) - biospace.com/
AVGR | $3.785 2.6K
|
Health Technology
|
| O: 20.26%
H: 1.81%
C: -6.35%
trial presentation
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.